[1]程 坤.醋酸钙联合碳酸镧治疗尿毒症血液透析高磷血症的疗效[J].医学信息,2021,34(18):155-157.[doi:10.3969/j.issn.1006-1959.2021.18.042]
　CHENG Kun.Efficacy of Calcium Acetate Combined with Lanthanum Carbonate in the Treatment of Uremic Hemodialysis Hyperphosphatemia[J].Medical Information,2021,34(18):155-157.[doi:10.3969/j.issn.1006-1959.2021.18.042]
点击复制

醋酸钙联合碳酸镧治疗尿毒症血液透析高磷血症的疗效()
分享到：

医学信息[ISSN:1006-1959/CN:61-1278/R]

卷:
34卷
期数:
2021年18期
页码:
155-157
栏目:
药物与临床
出版日期:
2021-09-18

文章信息/Info

Title:
Efficacy of Calcium Acetate Combined with Lanthanum Carbonate in the Treatment of Uremic Hemodialysis Hyperphosphatemia
文章编号:
1006-1959（2021）18-0155-03
作者:
程 坤
新沂市中医医院肾内科，江苏 新沂 221400
Author(s):
CHENG Kun
Department of Nephrology,Xinyi Hospital of Traditional Chinese Medicine,Xinyi 221400,Jiangsu,China
关键词:
醋酸钙; 碳酸镧; 尿毒症; 血液透析; 高磷血症
Keywords:
Calcium acetate; Lanthanum carbonate; Uremia; Hemodialysis; Hyperphosphatemia
分类号:
R692.5
DOI:
10.3969/j.issn.1006-1959.2021.18.042
文献标志码:
A
摘要:
目的 分析醋酸钙联合碳酸镧治疗尿毒症血液透析高磷血症的临床疗效。方法 选取2020年1月-2021年1月我院收治的95例尿毒症血液透析高磷血症患者作为研究对象，按照随机数字表法分为联合组（n=55）和对照组（n=40）。对照组仅通过醋酸钙进行治疗，联合组在对照组基础上给予碳酸镧治疗，比较两组临床疗效、血生化指标（血浆白蛋白、血红蛋白以及钙磷乘积）、血钙、血磷、甲状腺旁激素水平及并发症发生情况。结果 联合组治疗总有效率为96.36%，高于对照组的77.50%，差异有统计学意义（P＜0.05）。两组治疗后血浆白蛋白、血红蛋白较治疗前上升，钙磷乘积较治疗前下降，且联合组钙磷乘积低于对照组，差异有统计学意义（P＜0.05）。两组治疗后血磷、甲状腺旁激素较治疗前下降，血钙较治疗前上升，且联合组血磷、血钙、甲状腺旁激素优于对照组，差异有统计学意义（P＜0.05）；两组并发症总发生率比较，差异无统计学意义（P＞0.05）。结论 醋酸钙联合碳酸镧治疗尿毒症血液透析高磷血症具有良好的临床疗效，能有效改善患者血磷水平，且不增加并发症发生率，安全性较高。
Abstract:
Objective To analyze the clinical efficacy of calcium acetate combined with lanthanum carbonate in the treatment of uremic hemodialysis hyperphosphatemia.Methods A total of 95 patients with uremic hemodialysis and hyperphosphatemia admitted to our hospital from January 2020 to January 2021 were selected as the research objects.According to the random number table method, they were divided into a combination group (n=55) and a control group (n=40). The control group was treated with calcium acetate only, and the combination group was treated with lanthanum carbonate on the basis of the control group.The clinical efficacy, blood biochemical indicators (plasma albumin, hemoglobin, and calcium-phosphorus product), blood calcium, blood phosphorus and parathyroid hormone levels and complications were compared between the two groups.Results The total effective rate of treatment in the combined group was 96.36%, which was higher than 77.50% in the control group,the difference was statistically significant(P<0.05).After treatment, plasma albumin and hemoglobin increased compared with before treatment, and the product of calcium and phosphorus decreased compared with before treatment, and the product of calcium and phosphorus in the combination group was lower than that of the control group, the difference was statistically significant (P<0.05).After treatment, the blood phosphorus and parathyroid hormones of the two groups decreased compared with before treatment, and the blood calcium increased compared with before treatment. The combination group’s blood phosphorus, blood calcium, and parathyroid hormones were better than those of the control group, the difference was statistically significant (P<0.05);There was no significant difference in the total incidence of complications between the two groups (P>0.05).Conclusion Calcium acetate combined with lanthanum carbonate has a good clinical effect in the treatment of uremic hemodialysis hyperphosphatemia. It can effectively control the blood phosphorus level of the patient’s body without increasing the incidence of complications and has high safety.

参考文献/References:

[1]苏宏,李莹.醋酸钙胶囊联合碳酸镧咀嚼片治疗尿毒症血液透析患者高磷血症的临床疗效观察[J].吉林医学,2020,41(1):106-107.[2]徐金军,谭红金.醋酸钙和碳酸镧单独与联合应用治疗尿毒症血液透析高磷血症的效果对比[J].中外医学研究,2019,17(18):4-6. [3]Wilson RJ,Copley JB.Elemental calcium intake associated with calcium acetate/calcium carbonate in the treatment of hyperphosphatemia[J].Drugs Context,2017(6):212302.[4]李红梅,刘素,宗晓虹.醋酸钙联合碳酸镧治疗尿毒症血液透析高磷血症的疗效观察[J].现代药物与临床,2016,31(12):2041-2044. [5]李冠昉,朱赞东.醋酸钙和碳酸镧在尿毒症血液透析高磷血症治疗中的效果[J].实用中西医结合临床,2019,19(7):20-21. [6]Helal I,Elkateb H,Hedri H,et al.Efficacy and safety of calcium acetate-magnesium carbonate in the treatment of hyperphosphatemia in dialysis patients[J].Saudi J Kidney Dis Transpl,2016,27(6):1162.[7]郑伟平.30例尿毒症患者高磷血症给予醋酸钙联合高通量血液透析治疗的效果观察[J].现代诊断与治疗,2016,27(12):2206-2208.[8]刘航星.醋酸钙与高通量透析联合治疗尿毒症患者高磷血症的临床观察[J].中国继续医学教育,2016,8(7):160-161. [9]Cernaro V,Calimeri S,Laudani A,et al.Clinical Evaluation of the Safety,Efficacy and Tolerability of Lanthanum Carbonate in the Management of Hyperphosphatemia in Patients with End-Stage Renal Disease[J].Therapeutics and Clinical Risk Management,2020(16):871-880.[10]马益锋.醋酸钙联合高通量低钙透析治疗尿毒症患者高磷血症的疗效分析[J].现代诊断与治疗,2016,27(13):2426-2428.[11]江艳,黄珍伦,聂凌.碳酸镧治疗尿毒症维持性血液透析患者高磷血症的临床观察[J].中国药房,2017,28(20):2787-2789. [12]Yamashita H,Sakaguchi T,Kishikawa H,et al.Long-Term safety and efficacy of lanthanum carbonate in dialysis patients with hyperphosphatemia:6-Year Interim Analysis of Specified Drug Use-results Survey[J].Therapeutic Research,2017,38(3):267-279.[13]简汝堃,刘春花.碳酸镧治疗尿毒症维持性血液透析患者高磷血症的疗效[J].实用临床医学,2020,21(7):5-7,10. [14]邹贻武,莫代伟.碳酸镧治疗尿毒症维持性血液透析患者高磷血症的临床疗效[J].中国社区医师,2019,35(2):99,102. [15]徐金军,谭红金.醋酸钙和碳酸镧单独与联合应用治疗尿毒症血液透析高磷血症的效果对比[J].中外医学研究,2019,17(18):4-6.

相似文献/References:

[1]丘宝珍.碳酸镧治疗维持性血液透析患者高磷血症的疗效[J].医学信息,2019,32(24):148.[doi:10.3969/j.issn.1006-1959.2019.24.053]
　QIU Bao-zhen.Effect of Lanthanum Carbonate on Hyperphosphatemia in Patients with Maintenance Hemodialysis[J].Medical Information,2019,32(18):148.[doi:10.3969/j.issn.1006-1959.2019.24.053]

更新日期/Last Update: 1900-01-01